Herantis Pharma completes patient enrolment in Phase 1 study of Lymfactin gene therapy for secondary lymphedema … – GlobeNewswire (press release)
|
Herantis Pharma completes patient enrolment in Phase 1 study of Lymfactin gene therapy for secondary lymphedema …
GlobeNewswire (press release) Herantis Pharma Plc ("Herantis") has completed the patient enrolment in the clinical Phase 1 safety and tolerability study with the company's investigational gene therapy product Lymfactin® for the treatment of breast cancer associated secondary … |
